Please assess the completion status of the following clinical trial:

Trial Title: A Study of BAY3427080 (NT-814) in the Treatment of Moderate to Severe Post-menopausal Vasomotor Symptoms

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Key Inclusion Criteria:~* Postmenopausal~* Body mass index between 18 and 38 kg/m2, inclusive~* Subject experiences moderate or severe hot flashes~Key Exclusion Criteria:~* Inability to comply with the use of prohibited and allowed medications as described in the protocol.~* Any prior or ongoing history of clinically relevant drug or alcohol abuse within 12 months of Screening.~* Any clinically significant prior or ongoing history of arrhythmias, either determined through clinical history or on ECG evaluation.~* Any clinically significant abnormal laboratory test result(s) measured at Screening.~* Any active ongoing condition that could have caused difficulty in interpreting vasomotor symptoms.~* Uncontrolled hypertension.~* A history or hyperthyroidism, hypothyroidism or abnormal thyroid function tests at Screening. Treated hypothyroidism with normal thyroid function test results at Screening is acceptable.

- Gender: FEMALE
- Minimum Age: 40 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 160 mg Elinzanetant (BAY3427080) (Type: EXPERIMENTAL): Participants received 4x40 mg elinzanetant capsules.
- 120 mg Elinzanetant (BAY3427080) (Type: EXPERIMENTAL): Participants received 3x40 mg elinzanetant capsules and 1 placebo capsule.
- 80 mg Elinzanetant (BAY3427080) (Type: EXPERIMENTAL): Participants received 2x40 mg elinzanetant capsules and 2 placebo capsules.
- 40 mg Elinzanetant (BAY3427080) (Type: EXPERIMENTAL): Participants received one 40 mg elinzanetant capsule and 3 placebo capsules.
- Placebo (Type: PLACEBO_COMPARATOR): Participants received four placebo capsules orally once daily in the evening before bedtime.

Based on this trial design, predict the completion outcome and termination type (if applicable).